Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.

Inclusion Criteria:

• Patients with decompensated liver cirrhosis
• 18 years or older.
• Healthy individuals 18 years or older will serve as controls.

Exclusion Criteria:

• • Extrahepatic malignancy or recurrence of such within the last year.

  • Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
  • Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
  • Previous liver transplantation.
  • Transfusions the last 7 days.
  • Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken >12 hours after the last injection.

40 patients each with NAD, AD and ACF and 30 healthy volunteers.